Skip to main content
SpringerLink
Log in

CSE-Hemmer: Besitzen Hydrophilie oder Lipophilie dieser Substanzen eine klinische Relevanz?

  • Conference paper
Hyperlipoproteinämie

  • 21 Accesses

Zusammenfassung

Die neu entwickelten HMG-CoA-Reduktase-Inhibitoren stellen aufgrund ihres klar definierten Wirkmechanismus, ihrer hohen klinischen Wirksamkeit und ihrer einfachen Applikationsform einen wesentlichen Fortschritt in der Therapie von Fettstoffwechselstörungen dar. Derzeit sind in Deutschland drei Cholesterinsynthese-Enzymhemmer, nämlich Lovastatin, Simvastatin und Pravastatin verfügbar. Die lipophilen CSE-Hemmer Lovastatin und Simvastatin sind Prodrugs, die nach oraler Applikation durch ubiquitär vorkommende Esterasen in ihre aktive ß-Hydroxysäureform überführt werden. Das hydrophile Pravastatin weist dagegen von vornherein die aktive ß-Hydroxy- säureform auf. Gerade diese unterschiedlichen Charakteristika der CSE- Hemmer - Prodrug versus aktive Form, Hydrophilie versus Lipophilie - werden derzeit im Hinblick auf ihre klinische Relevanz kontrovers diskutiert (24).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Barth ID, Kruisbrink OA, Van Dijk AL (1990) Inhibitors of hydroxymethylglu- taryl coenzyme A reductase for treating hypercholesterolemia. Br Med J 301:669.

    Article  CAS  Google Scholar 

  2. BMS, pers. Information vom Hersteller (1991).

    Google Scholar 

  3. Betteridge DJ (1991) FdM, 109 (106), Pravastatin, zuverlässige Wirkung in der Langzeittherapie, 5–7.

    Google Scholar 

  4. Boccuzzi SJ, Bocanegra TS, Walker JF, Shapiro DR, Keegan ME (1991) Long- Term Safety and Efficacy Profile of Simvastatin. Am J Cardiol 68:1127–1131.

    Article  PubMed  CAS  Google Scholar 

  5. Botti RE, Triscari J, Pan HY, Zagat J (1991) Concentrations of Pravastatin and Lovastatin in Cerebrospinal Fluid in Healthy Subjects. Clinical Neuropharmacology 14 (3):256–261.

    Article  PubMed  CAS  Google Scholar 

  6. Bradford RH et al (1991a) Expanded Clinical Evaluation of Lovastatin (EXCEL) Study Results. I. Efficacy in Modifying Plasma Lipoproteins and Adverse Event Profile in 8245 Patients With Moderate Hypercholesterolemia. Arch Intern Med 151:43.

    Article  PubMed  CAS  Google Scholar 

  7. Bradford RH, Chremos AN, Shear CN, Higgins J (1991b) Long-Term Safety and Efficacy of Lovastatin. Results from 977 Patients Treated for Two Years in the Expanded Clinical Evaluation of Lovastatin (EXCEL) Study. The Challenges of Atherosclerosis: From Research to Clinical Practice. Lisbon, May 24.

    Google Scholar 

  8. Catalano PM, Masonson HN, Newmann TJ, Alexander JC (1989) Clinical safety of Pravastatin. Roy Soc Med Serv 35–38.

    Google Scholar 

  9. Dreyer M, Dammann HG (1991) Pravastatin. Ein hydrophiler und leberselektiver Hemmstoff der Cholesterinbiosynthese. Arzneimitteltherapie 9 (9): 264–273.

    Google Scholar 

  10. Duggan DE, Chen IW, Bayne WF, Helpin RA, Duncan CA, Schwartz MS, Stubbs RJ, Vickers S (1989) The Physiological Disposition of Lovastatin. Drug Met. Dis- po. 17 (2):166–173.

    CAS  Google Scholar 

  11. Forth W, Henschler D, Rummel W (1987) Allgemeine und spezielle Pharmakologie und Toxikologie. Wissenschaftsverlag, Mannheim/Wien/Zürich.

    Google Scholar 

  12. Germershausen JL, Hunt VW, Bostedor RG, Baüy PJ, Karkas JD, Alberts AW (1989) Tissue selectivity of the cholesterol-lowerin agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochem Biophys Res Commun 158 (3): 667–675.

    Article  PubMed  CAS  Google Scholar 

  13. Grundy SM (1988) HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 319:24–33.

    Article  PubMed  CAS  Google Scholar 

  14. Halstenson ChE, Triscari J, de Vault A, Shapiro B, Keane W, Pan H (1992) Single dose pharmacokinetics of pravastatin and metabolites in patients with renal un pairment. J Clin Pharmacol 32:124–132.

    PubMed  CAS  Google Scholar 

  15. Koga T, Shimada Y, Kuroda M, Tsujita Y, Hasegawa K, Yamazaki M (1990) Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochem Biophys Acta 1045:115–120.

    PubMed  CAS  Google Scholar 

  16. Mevacor, US-Fachinformation (1991).

    Google Scholar 

  17. Pan HY (1990) HMG-CoA reductase inhibitors: Clinical pharmacology. In: Got- to AM Jr, Mancini M, Richter WO, Schwandt P (eds): Treatment of severe hypercholesterolemia in the prevention of coronary heart disease - 2. 66–70. Prac 2nd Int Symp Munich 1989. Basel, Karger.

    Google Scholar 

  18. Pan HY, De Vault AR, Wang-Iverson D, Ivashkiv E, Swanson BN, Sugerman A A (1990) Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol 30:1128–1135.

    PubMed  CAS  Google Scholar 

  19. Parker RA, Clark RW, Sit S-Y, Lanier TL, Grosso RA, Wright JJK (1990) Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors. J Lipid Res 31:1271–1282.

    PubMed  CAS  Google Scholar 

  20. Pierce R, Wysowski DK, Gross ThP (1990) Myopathy and Rhabdomyolysis associated with Lovastatin - Gemfibrocil combination therapy. JAMA 264:71–75.

    Article  PubMed  CAS  Google Scholar 

  21. Querins S, Lambert R, Cusson JR, Grégoire S, Vickers S, Stubbs RJ, Sweany AE, Larochelle P (1991) Single dose pharmacokinetics of 14C-lovastatin in chronic renal failure. Clin Pharmacol Ther 50:437–441.

    Article  Google Scholar 

  22. Roth Th, Richardson GR, Sullivan JP, Lee RM, Merlotti L, Roehrs T (1992) Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance. Clin Cardiol 15:426–432.

    Article  PubMed  CAS  Google Scholar 

  23. Schäfer EJ (1988) HMG-CoA reductase inhibitors for hypercholesterolemia (letter to the editor). N Engl J Med 319:1222.

    Article  Google Scholar 

  24. Schunack W (1991) CSE-Hemmer. Wirkung oder Nebenwirkung hängen nicht von der Hydrophilie oder Lipophilie ab! Der Kassenarzt 35:45–46.

    Google Scholar 

  25. Serajuddin ATM, Ranadive SA, Mahoney EM (1991) Relative Lipophilities, Solubilities, and Structure-Pharmacological Considerations of 3-Hydroxy-3-Methyl- glutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitors Pravastatin, Lovastatin, Mevastatin, and Simvastatin. J Pharmaceut Sciences 80, 9:830–834.

    Article  CAS  Google Scholar 

  26. Singhoi SM, Pan HY, Morrison RA, Willard DA (1990) Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J clin Pharmac 29:239–243.

    Google Scholar 

  27. Tsujita Y, Watanabe Y (1989) Pravastatin sodium: a novel cholesterol-lowering agent that inhibits HMG-CoA reductase. Cardiovasc Drug Rev 7 (2): 110–126.

    Article  Google Scholar 

  28. Vgontzas AN, Kales A, Bixler EO, Manfredi RL, Tyson KL (1991) Effects of lovastatin and pravastatin on sleep efficacy and sleep stages. Clin Pharmacol Ther 50:730–7.

    Article  PubMed  CAS  Google Scholar 

  29. Yoshimura M et al. (1991) Treatment of hypercholesterolemia with a new HMG- CoA reductase inhibitor, pravastatin, in renal transplant recipents. Amer Soc Transplant Physicians, Abstract, Pl-27, Chicago.

    Google Scholar 

  30. Zocor, US-Fachinformation (1992).

    Google Scholar 

Download references

Authors
  1. H. G. Dammann
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abt. für Endokrinologie u. Stoffwechsel, Klinikum der Philipps-Universität Zentrum für Innere Medizin, Baldingerstraβe, D-3350, Marburg, Deutschland

    Jürgen Schneider , Armin Steinmetz  & Hans Kaffarnik ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Dammann, H.G. (1992). CSE-Hemmer: Besitzen Hydrophilie oder Lipophilie dieser Substanzen eine klinische Relevanz?. In: Schneider, J., Steinmetz, A., Kaffarnik, H. (eds) Hyperlipoproteinämie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77813-1_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-77813-1_4

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-55968-9

  • Online ISBN: 978-3-642-77813-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation